

# Cabo Verde

Population 2015

<1 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	0.027 (0.026–0.029)	5.3 (4.9–5.6)
Mortality (HIV+TB only)	0.037 (0.024–0.051)	7 (4.7–9.9)
Incidence (includes HIV+TB)	0.72 (0.47–1)	139 (90–198)
Incidence (HIV+TB only)	0.084 (0.053–0.12)	16 (10–23)
Incidence (MDR/RR-TB)**	0.027 (0–0.055)	5.2 (0–11)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	0 (0–0.032)	0.16 (<0.01–0.31)	0.16 (0–0.35)
Males	0.084 (0.05–0.12)	0.48 (0.33–0.63)	0.56 (0.38–0.75)
Total	0.084 (0.054–0.11)	0.64 (0.48–0.8)	0.72 (0.47–1)

## TB case notifications, 2015

Total cases notified	272
Total new and relapse	269
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	100%
- % pulmonary	90%
- % bacteriologically confirmed among pulmonary	82%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	37% (26–57)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.09 (0.06–0.14)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	31	12%
- on antiretroviral therapy	24	77%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			11 (1–21)
Estimated % of TB cases with MDR/RR-TB	2.8% (0.1–6.7)	21% (2.2–39)	
% notified tested for rifampicin resistance			0
MDR/RR-TB cases tested for resistance to second-line drugs			0
Laboratory-confirmed cases		MDR/RR-TB: 0, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 0, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	92%	276
Previously treated cases, excluding relapse, registered in 2014	58%	19
HIV-positive TB cases, all types, registered in 2014	85%	27
MDR/RR-TB cases started on second-line treatment in 2013		0
XDR-TB cases started on second-line treatment in 2013		0

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	76%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

## TB financing, 2016

National TB budget (US\$ millions)	<1
Funding source: 95% domestic, 5% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015



## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)

